Higher standards needed for human clinical drug trials

News

A recent commentary written by McGill’s Dr. Jonathan Kimmelman and colleagues, argues that some painful procedures used in clinical trials, such as serial biopsies of patients with advanced cancer seeking treatment are not well thought out, leading to unnecessary burden for patients in trials.

Most information in drug development is lost

Research

Lots of potentially useful medical information is getting lost. McGill researchers discovered this when they looked into the lack of reporting of information from “stalled drug” trials in cancer, cardiovascular and neurological diseases. “Stalled drugs” are drugs that fail to make it to the market either because they prove to be ineffective or unsafe or both. Because only one in ten of the drugs that goes into human testing actually gets licensed, most of the information collected in developing new drugs is currently being lost. This is despite the fact that this information is critical for effective care, protecting patients, and discovering better drugs.